このエントリーをはてなブックマークに追加
ID 46943
フルテキストURL
著者
Ochiai, Kazuhiko Innovation Center Okayama for Nanobio-Targeted Therapy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Watanabe, Masami Innovation Center Okayama for Nanobio-Targeted Therapy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Ueki, Hideo Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Huang, Peng Innovation Center Okayama for Nanobio-Targeted Therapy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Fujii, Yasuyuki Innovation Center Okayama for Nanobio-Targeted Therapy, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Nasu, Yasutomo Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Noguchi, Hirofumi Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Hirata, Takeshi Department of Urology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Sakaguchi, Masakiyo Department of Cell Biology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Huh, Nam-ho Department of Cell Biology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University
Kashiwakura, Yuji
抄録
Persistent hepatitis C virus (HCV) infection causes chronic liver diseases and is a global health problem. HuH-7 hepatoma-derived cells are widely used as the only cell-based HCV replication system for HCV research, including drug assays. Recently, using different hepatoma Li23-derived cells, we developed an HCV drug assay system (ORL8), in which the genome-length HCV RNA (O strain of genotype 1b) encoding renilla luciferase replicates efficiently. In this study, using the HuH-7-derived OR6 assay system that we developed previously and the ORL8 assay system, we evaluated 26 anti-HCV reagents, which other groups had reported as anti-HCV candidates using HuH-7-derived assay systems other than ORB. The results revealed that more than half of the reagents showed different anti-HCV activities from those in the previous studies, and that anti-HCV activities evaluated by the ORB and ORL8 assays were also frequently different. In further evaluation using the HuH-7-derived AH1R assay system, which was developed using the AH1 strain of genotype 1b, several reagents showed different anti-HCV activities in comparison with those evaluated by the OR6 and ORL8 assays. These results suggest that the different activities of anti-HCV reagents are caused by the differences in cell lines or HCV strains used for the development of assay systems. Therefore, we conclude that plural HCV assay systems developed using different cell lines or HCV strains are required for the objective evaluation of anti-HCV reagents.
キーワード
REIC
Dkk-3
Tctex-1
Dynein
Endoplasmic reticulum
Two-hybrid screening
発行日
2011-08-26
出版物タイトル
Biochemical and Biophysical Research Communications
412巻
2号
出版者
Academic Press Inc Elsevier Science
開始ページ
391
終了ページ
395
ISSN
0006-291X
NCID
AA00564395
資料タイプ
学術雑誌論文
言語
English
OAI-PMH Set
岡山大学
著作権者
© 2011 Elsevier Inc. All rights reserved.
論文のバージョン
author
査読
有り
DOI
PubMed ID
Web of Sience KeyUT